Recombinant Anti-Jagged1 antibody [EPR4290] (ab109536)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR4290] to Jagged1
- Suitable for: WB
- Knockout validated
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Jagged1 antibody [EPR4290]
See all Jagged1 primary antibodies -
Description
Rabbit monoclonal [EPR4290] to Jagged1 -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details
Unsuitable for: ICC/IF or IHC-P -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: HepG2 and HUVEC whole cell lysate, NIH:OVCAR-3 cell lysate.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20ºC. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 40% Glycerol, 59% PBS, 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR4290 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab109536 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (2) |
1/1000 - 1/10000. Predicted molecular weight: 134 kDa.
|
Notes |
---|
WB
1/1000 - 1/10000. Predicted molecular weight: 134 kDa. |
Target
-
Function
Ligand for multiple Notch receptors and involved in the mediation of Notch signaling. May be involved in cell-fate decisions during hematopoiesis. Seems to be involved in early and late stages of mammalian cardiovascular development. Inhibits myoblast differentiation (By similarity). Enhances fibroblast growth factor-induced angiogenesis (in vitro). -
Tissue specificity
Widely expressed in adult and fetal tissues. In cervix epithelium expressed in undifferentiated subcolumnar reserve cells and squamous metaplasia. Expression is up-regulated in cervical squamous cell carcinoma. Expressed in bone marrow cell line HS-27a which supports the long-term maintenance of immature progenitor cells. -
Involvement in disease
Defects in JAG1 are the cause of Alagille syndrome type 1 (ALGS1) [MIM:118450]. Alagille syndrome is an autosomal dominant multisystem disorder defined clinically by hepatic bile duct paucity and cholestasis in association with cardiac, skeletal, and ophthalmologic manifestations. There are characteristic facial features and less frequent clinical involvement of the renal and vascular systems.
Defects in JAG1 are a cause of tetralogy of Fallot (TOF) [MIM:187500]. TOF is a congenital heart anomaly which consists of pulmonary stenosis, ventricular septal defect, dextroposition of the aorta (aorta is on the right side instead of the left) and hypertrophy of the right ventricle. This condition results in a blue baby at birth due to inadequate oxygenation. Surgical correction is emergent. -
Sequence similarities
Contains 1 DSL domain.
Contains 15 EGF-like domains. -
Developmental stage
Expressed in 32-52 days embryos in the distal cardiac outflow tract and pulmonary artery, major arteries, portal vein, optic vesicle, otocyst, branchial arches, metanephros, pancreas, mesocardium, around the major bronchial branches, and in the neural tube. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 182 Human
- Entrez Gene: 16449 Mouse
- Entrez Gene: 29146 Rat
- Omim: 601920 Human
- SwissProt: P78504 Human
- SwissProt: Q9QXX0 Mouse
- SwissProt: Q63722 Rat
- Unigene: 224012 Human
see all -
Alternative names
- AGS antibody
- AHD antibody
- AWS antibody
see all
Images
-
All lanes : Anti-Jagged1 antibody [EPR4290] (ab109536) at 1/10000 dilution
Lane 1 : HepG2 (human hepatocellular carcinoma epithelial cell), whole cell lysate
Lane 2 : HUVEC (human umbilical vein endothelial cell), whole cell lysate
Lane 3 : Jurkat (human T cell leukemia T lymphocyte), whole cell lysate
Lane 4 : MOLT-4 (human lymphoblastic leukemia T lymphoblast), whole cell lysate
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 134 kDa
Observed band size: 200, 23 kDa why is the actual band size different from the predicted?
Exposure time: 180 secondsBlocking buffer and concentration: 5% NFDM/TBST
Diluting buffer and concentration: 5% NFDM /TBSTNegative controls: Jurkat and MOLT-4 whole cell lysate (PMID: 30231940)
200-kDa full length and 23-kDa C-terminal JAG1 are observed. The molecular weights are consistent with what has been described in the literature (PMID: 30890522, 30890522).
This blot was developed using a high sensitivity ECL substrate.
-
All lanes : Anti-Jagged1 antibody [EPR4290] (ab109536) at 1/10000 dilution
Lane 1 : Wild-type HAP1 whole cell lysate
Lane 2 : JAG1 knockout HAP1 whole cell lysate
Lysates/proteins at 20 µg per lane.
Predicted band size: 134 kDa
Observed band size: 200 kDa why is the actual band size different from the predicted?Lanes 1 - 2: Merged signal (red and green). Green - ab109536 observed at 200 kDa. Red - loading control, ab9484, observed at 37 kDa.
ab109536 was shown to recognize in wild-type HAP1 cells as signal was lost at the expected MW in JAG1 knockout cells. Additional cross-reactive bands were observed in the wild-type and knockout cells. Wild-type and JAG1 knockout samples were subjected to SDS-PAGE. Ab109536 and ab9484 (Mouse anti GAPDH loading control) were incubated overnight at 4°C at 1/10000 dilution and 1/20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/20000 dilution for 1 hour at room temperature before imaging.
-
Anti-Jagged1 antibody [EPR4290] (ab109536) at 1/1000 dilution (Purified) + HepG2 at 10 µg
Secondary
HRP goat anti-rabbit (H+L) at 1/1000 dilution
Predicted band size: 134 kDa
Observed band size: 200 kDa why is the actual band size different from the predicted?Blocking buffer: 5% NFDM/TBST
Dilution buffer: 5% NFDM/TBST
-
All lanes : Anti-Jagged1 antibody [EPR4290] (ab109536) at 1/10000 dilution (Unpurified)
Lane 1 : HepG2 cell lysate
Lane 2 : NIH:OVCAR-3 cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP-labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 134 kDa
Observed band size: 200 kDa why is the actual band size different from the predicted?
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (52)
ab109536 has been referenced in 52 publications.
- Yu L & Li J Punicalagin Alleviates Aged Bronchial Asthma by Inhibiting Th2 Differentiation through IL-4/STAT6 and Jagged1/Notch Pathways. J Healthc Eng 2022:1184677 (2022). PubMed: 35140898
- Hosoya M et al. Early development of the cochlea of the common marmoset, a non-human primate model. Neural Dev 17:6 (2022). PubMed: 35524278
- Saeki T et al. Critical roles of FGF, RA, and WNT signalling in the development of the human otic placode and subsequent lineages in a dish. Regen Ther 20:165-186 (2022). PubMed: 35620640
- Geles KG et al. NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells. Cell Rep Med 2:100279 (2021). PubMed: 34095881
- Zhang Y et al. Loss of Apc Cooperates with Activated Oncogenes to Induce Liver Tumor Formation in Mice. Am J Pathol 191:930-946 (2021). PubMed: 33545120